Q1 FY2027 · ended Aug 31, 2026 · Revenue $257.15M, +22.7% YoY · Filed Oct 8, 2026
Tilray Brands, Inc. (TLRY) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q1 of fiscal 2027, the quarter ended Aug 31, 2026, it reported revenue of $257.1 million and a net loss of $43.1 million. As of Aug 31, 2026 it held $224.4 million in cash and investments and $297.2 million in total debt.
Revenue
$257.15M
+22.7% vs year-ago quarter
Net income
$-43.14M
-13297.8% vs year-ago quarter
Operating cash flow
$-16.54M
-1133.5% vs year-ago quarter
Free cash flow
$-19.14M
+5.1% vs prior quarter
EPS
$-0.32
Dividend per share
None
Shares outstanding
147.79M
-86.8% vs year-ago quarter
Net cash
$-72.87M
Q1 FY2027
Operating margin
-9.3%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TLRY (Nasdaq)
- Fiscal year ends
- May 31
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1731348
- Former names
- Tilray, Inc. (until Jan 10, 2022)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Aug 31, 2026 |
Q4 FY2026 May 31, 2026 |
Q3 FY2026 Feb 28, 2026 |
Q2 FY2026 Nov 30, 2025 |
Q1 FY2026 Aug 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $257.1M | $281.7M | $206.7M | $217.5M | $209.5M |
| Operating income | -$24.1M | -$16.5M | -$26.4M | -$22.3M | $2.1M |
| Net income | -$43.1M | -$49.6M | -$26.6M | -$44.9M | -$322,000 |
| Diluted EPS | -$0.32 | -$0.42 | -$0.24 | -$0.41 | $0.00 |
| Operating cash flow | -$16.5M | -$37.3M | -$21.9M | -$8.5M | -$1.3M |
| Total assets | $2.3B | $2.3B | $2.1B | $2.1B | $2.1B |
| Total liabilities | $721.3M | $733.1M | $549.1M | $552.1M | $562.0M |
| Stockholders' equity | $1.6B | $1.6B | $1.6B | $1.6B | $1.5B |
| Cash and investments | $224.4M | $237.8M | $227.6M | $304.9M | $275.0M |
| Total debt | $297.2M | $180.3M | $76.4M | $77.7M | $79.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 8, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 8, 2026 | Oct 8, 2026 |
| ARS | Annual report to shareholders | Sep 28, 2026 | May 31, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 14, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Aug 10, 2026 | Aug 4, 2026 |
| 10-K | Annual report | Jul 28, 2026 | May 31, 2026 |
All 770 Tilray Brands, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.